Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (91-100 of 791) with videos related to

Pageof 80
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2012
Nilotinib-associated vascular eventsAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Clinical Case Reports|August 28, 2018
Acute respiratory syndrome following accidental inhalation of mercury vaporJorge Cortes, Jaime Peralta, Rienzi Díaz-Navarro
The New England Journal of Medicine|October 13, 2007
Tyrosine kinase inhibitors for chronic myelogenous leukemiaAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Cancer|September 10, 2009
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Nature Reviews. Drug Discovery|September 15, 2007
Flying under the radar: the new wave of BCR-ABL inhibitorsAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Clinical Advances in Hematology & Oncology : H&O|November 29, 2012
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemiaJorge Cortes, Jerald Radich, Michael J Mauro
Best Practice & Research. Clinical Haematology|March 6, 2003
New agents in the treatment of acute lymphocytic leukaemiaDeborah A Thomas, Jorge Cortes, Hagop M Kantarjian
Expert Review of Anticancer Therapy|July 11, 2009
Azacitidine for the treatment of myelodysplastic syndromeVince D Cataldo, Jorge Cortes, Alfonso Quintás-Cardama
Expert Opinion on Pharmacotherapy|November 16, 2010
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemiaAmber Fullmer, Hagop Kantarjian, Jorge Cortes, et al.
Cancer|February 15, 2011
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.
Pageof 80

Showing results (91-100 of 791) with videos related to

Sort By:
Pageof 80
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2012
Nilotinib-associated vascular eventsAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Clinical Case Reports|August 28, 2018
Acute respiratory syndrome following accidental inhalation of mercury vaporJorge Cortes, Jaime Peralta, Rienzi Díaz-Navarro
The New England Journal of Medicine|October 13, 2007
Tyrosine kinase inhibitors for chronic myelogenous leukemiaAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Cancer|September 10, 2009
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Nature Reviews. Drug Discovery|September 15, 2007
Flying under the radar: the new wave of BCR-ABL inhibitorsAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Clinical Advances in Hematology & Oncology : H&O|November 29, 2012
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemiaJorge Cortes, Jerald Radich, Michael J Mauro
Best Practice & Research. Clinical Haematology|March 6, 2003
New agents in the treatment of acute lymphocytic leukaemiaDeborah A Thomas, Jorge Cortes, Hagop M Kantarjian
Expert Review of Anticancer Therapy|July 11, 2009
Azacitidine for the treatment of myelodysplastic syndromeVince D Cataldo, Jorge Cortes, Alfonso Quintás-Cardama
Expert Opinion on Pharmacotherapy|November 16, 2010
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemiaAmber Fullmer, Hagop Kantarjian, Jorge Cortes, et al.
Cancer|February 15, 2011
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.
Pageof 80